{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.5.6.3', 'Week 3', '96', '9.5.6.4', 'Week 4', '97', '9.5.6.5', 'Week 6', '97', '9.5.6.6', 'Week 9', '98', '9.5.6.7', 'Week 12', '98', '9.5.6.8', 'Week 15', '99', '9.5.6.9', 'Week 18', '100', '9.5.6.10 Week 21', '100', '9.5.6.11 Week 24/Premature Withdrawal - Treatment Period', '101', '9.5.6.12 Month 7 - Follow-Up Period', '101', '9.5.6.13 Month 9 - Follow-Up Period', '102', '9.5.6.14 Month 12', '102', '9.5.6.14.1 Month 12/Premature Withdrawal - Follow-Up Period for Proptosis', 'Non-responders in Study HZNP-TEP-301', '102', '9.5.6.14.2 Month 12 - Follow-Up Contact for Subjects Who Relapsed in', 'Study HZNP-TEP-301', '103', '9.5.6.15 Month 18', '103', '9.5.6.15.1 Month 18 - Follow-Up Contact for Proptosis Non-responders in', 'Study HZNP-TEP-301', '103', '9.5.6.15.2 Month 18 - Follow-Up Contact for Subjects Who Relapsed in', 'Study HZNP-TEP-30', '103', '9.5.6.16 Month 24 - Follow-Up Contact for Proptosis Non-responders in', 'Study HZNP-TEP-301', '103', '9.6', 'Statistical Methods and Determination of Sample Size', '104', '9.6.1', 'Endpoints', '104', '9.6.1.1', 'Primary Endpoint', '104', '9.6.1.2 Secondary Endpoints', '104', '9.6.1.3 Exploratory Endpoints', '104', '9.6.2', 'Populations for Analysis', '105', '9.6.3', 'Primary and Secondary Endpoint Analysis', '105', '9.6.3.1 Clinical Measures of Severity', '105', '9.6.3.1.1', 'Motility Component of the Clinical Measures of Severity', '105', '9.6.3.2 Clinical Activity Score (CAS)', '105', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 41 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.6.3.2.1', 'Stratification of Proptosis and CAS Response into Four Responses', 'Categories', '105', '9.6.3.3 Quality of Life Analysis', '106', '9.6.3.4 Safety Analyses', '106', '9.6.3.5 Interim Analyses', '106', '9.6.4', 'Sample Size and Power Considerations', '106', '9.7 Changes in the Conduct of the Study', '106', '10', 'SOURCE DOCUMENTATION AND INVESTIGATOR FILES', '107', '11', 'CASE REPORT FORMS', '107', '12', 'STUDY MONITORING', '108', '13', 'DATA MANAGEMENT', '109', '14', 'RETENTION OF RECORDS', '109', '15 PUBLICATION', '110', '16 REFERENCES', '110', '17 APPENDICES', '116', '17.1', 'Administrative Appendix', '116', '17.2 Proptosis (Exophthalmometry) Method', '117', \"17.3 Graves' Ophthalmopathy Quality of Life Questionnaire\", '118', 'LIST OF TABLES', 'Table 6.1 Table of Non-Sponsor Study Responsibilities', '50', 'Table 7.1', 'Single-Dose Pharmacokinetic Parameters (CHO Material)', '59', 'Table 7.2', 'Summary of TEAEs Reported in at Least 5% of Subjects in Teprotumumab', 'Treatment Group and % is Greater Than Placebo', '61', 'Table 7.3', 'Summary of SAEs Reported in Either Treatment Group by Preferred Term', '62', 'Table 9.1', 'Restricted Medications and Therapies', '81', 'Table 9.2', 'Clinical Activity Score (CAS) Assessment', '83', 'Table 9.3', 'Clinical Measures of Severity', '84', 'Table 9.4', 'Schedule of Clinical Laboratory Safety Tests, Including Thyroid Panel and', 'Hyperglycemia Monitoring', '93', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 42 of 118']\n\n###\n\n", "completion": "END"}